ライフサイエンスコーパス: atrial appendage

1 e first bifurcation and thrombus in the left atrial appendage.

2 , septal bags (6) and 1 thrombus in the left atrial appendage.

3 n the posterior left atrium than in the left atrial appendage.

4 en the left superior pulmonary vein and left atrial appendage.

5 to the rest of the atria, ending at the left atrial appendage.

6 nantly because of interference from the left atrial appendage.

7 into the distal coronary sinus and the right atrial appendage.

8 e normal pericardial space through the right atrial appendage.

9 oach from a femoral vein to pierce the right atrial appendage.

10 e distal coronary sinus and one in the right atrial appendage.

11 culae and the crista terminalis of the right atrial appendage.

12 sinus activation during pacing from the left atrial appendage.

13 within the left atrium and posterior to the atrial appendage.

14 gament disruption, and exclusion of the left atrial appendage.

15 was inserted into the incision in the right atrial appendage.

16 Myofibroblasts were not detected in the left atrial appendage.

17 All patients underwent closure of the left atrial appendage.

18 y in CV was found between the right and left atrial appendages.

19 HCAs were dissected from right atrial appendages.

20 cardial adipose tissues, myocardia, and left atrial appendages.

21 ime of first AF recurrence at both the right atrial appendage (161+/-22 vs 167+/-26 ms, P=0.05) and d

22 MV leaflets), interatrial septum (84%), left atrial appendage (86%), and left ventricle (77%) was obs

23 NO* concentration was decreased in the left atrial appendage, although NOS expression was not affect

24 Electrodes were positioned in the right atrial appendage and coronary sinus in 13 patients.

25 We measured AFCL at the right atrial appendage and distal coronary sinus before attemp

26 , and morphological features, including left atrial appendage and left atrium-related characteristics

27 he coronary sinus (CS) cephalad, between the atrial appendage and left pulmonary veins, was dissected

28 s, the anterior part of the septum, the left atrial appendage and the superior vena cava.

29 CACs and CSCs were cultured from left atrial appendages and blood samples obtained from patien

30 omyocytes were isolated from collected right atrial appendages and Ca2+ handling (L-type Ca2+ current

31 of AF, emphasize the importance of the left atrial appendage, and consider challenges and future dir

32 d from the left ventricle (VP, n=29) or left atrial appendage (AP, n=12) to induce CM.

33 vices such as occluders of a PFO or the left atrial appendage are preferred in patients with an incre

34 premature atrial contractions, from the left atrial appendage at a coupling interval of 200 ms in 7 h

35 cro m, n=71) were dissected from human right atrial appendages at the time of cardiac surgery and can

36 +/-5 microm, n=70) were dissected from right atrial appendages at the time of cardiac surgery and can

37 itional sites including the tip of the right atrial appendage, at the fossa ovalis, and in the distal

38 Biopsies were obtained from the right atrial appendage before and after aortic cross-clamping.

39 or cross-sectional study and collected right atrial appendage biopsies.

40 of decorin protein core, uncovered in human atrial appendages, can regulate the local bioavailabilit

41 fter pulmonary vein isolation, complete left atrial appendage closure (0 mm residual communication) w

42 Left atrial appendage closure (LAAC) and nonwarfarin oral ant

43 As the use of left atrial appendage closure (LAAC) becomes more widespread,

44 term data on the safety and efficacy of left atrial appendage closure (LAAC) for stroke prevention in

45 ught to assess composite data regarding left atrial appendage closure (LAAC) in 2 randomized trials c

46 Percutaneous left atrial appendage closure (LAAC) is noninferior to vitami

47 on coagulation system activation after left atrial appendage closure (LAAC) remains unknown.

48 The risk-benefit ratio of left atrial appendage closure (LAAC) versus systemic therapy

49 Left atrial appendage closure (LAAC) was approved by the U.S.

50 to evaluate the results associated with left atrial appendage closure (LAAC) with the AMPLATZER Cardi

51 l Fibrillation) trial demonstrated that left atrial appendage closure (LAAC) with the Watchman device

52 lated thrombus (DRT) after percutaneous left atrial appendage closure (LAAC).

53 AF trial who underwent attempted device left atrial appendage closure (n=542 patients) and those from

54 Watchman Device in Patients Undergoing Left Atrial Appendage Closure [SWISS-APERO]; NCT03399851).

55 (PROTECT AF) randomized trial compared left atrial appendage closure against warfarin in atrial fibr

56 Safety data on percutaneous left atrial appendage closure arises from centers with consid

57 rtic Valve Surgery), and LAACS-2 trial (Left Atrial Appendage Closure by Surgery-2) will help define

58 The implantation of left atrial appendage closure device (WATCHMAN, Boston Scient

59 tack, or thromboembolism) score >/=1, a left atrial appendage closure device is noninferior to long-t

60 dated overview of current transcatheter left atrial appendage closure devices and review the results

61 d occurred in 65 patients (8.5%) in the left atrial appendage closure group (device group) and in 137

62 Over the past decade, percutaneous left atrial appendage closure has emerged as a valid alternat

63 ular AF at risk for stroke treated with left atrial appendage closure have favorable QOL changes at 1

64 e successfully isolated with subsequent left atrial appendage closure in 57 patients.

65 Left atrial appendage closure is a mechanical alternative to

66 Left atrial appendage closure is an alternative to chronic or

67 e outcomes associated with percutaneous left atrial appendage closure is higher in the real-world pop

68 The "local" strategy of left atrial appendage closure is noninferior to "systemic" an

69 erse outcomes and costs of percutaneous left atrial appendage closure procedure in the US.

70 , including radiofrequency ablation and left atrial appendage closure procedures for patients with AF

71 Plavix Feasibility Study With Watchman Left Atrial Appendage Closure Technology [ASAP]; NCT00851578)

72 In the PROTECT AF (Watchman Left Atrial Appendage Closure Technology for Embolic Protecti

73 llation patients receiving the WATCHMAN left atrial appendage closure technology was designed to coll

74 llation Patients Receiving the WATCHMAN Left Atrial Appendage Closure Technology, patients with a WAT

75 e for each antithrombotic regimen after left atrial appendage closure to provide tools to guide the p

76 (PRAGUE-17 [Left Atrial Appendage Closure vs Novel Anticoagulation Agents

77 (Left Atrial Appendage Closure vs. Novel Anticoagulation Agent

78 Left Atrial Appendage Closure vs. Novel Anticoagulation Agent

79 ter-based atrial fibrillation ablation, left atrial appendage closure was associated with a lower ris

80 ucted to determine whether percutaneous left atrial appendage closure with a filter device (Watchman)

81 t improvement in the safety of Watchman left atrial appendage closure with increased operator experie

82 Left atrial appendage closure with the device (n = 463) or wa

83 or patient's self-management [PSM] and left atrial appendage closure) are based on the concept of co

84 Watchman Device in Patients Undergoing Left Atrial Appendage Closure) trial, patients with atrial fi

85 chman/FLX Device in Patients Undergoing Left Atrial Appendage Closure), patients undergoing LAA closu

86 In more than 10 years experience with left atrial appendage closure, a wide range of antithrombotic

87 f 803 patients were assigned to undergo left atrial appendage closure, and 797 to receive anticoagula

88 ure (mitral and tricuspid valve repair, left atrial appendage closure, and paravalvular leak closure)

89 optimal antithrombotic treatment after left atrial appendage closure, effective on both device-relat

90 and review the results associated with left atrial appendage closure, focusing on procedural and lat

91 tion of DRT is detected >6 months after left atrial appendage closure, highlighting the need for imag

92 During left atrial appendage closure, the estimated dose absorbed by

93 xperience on the safety of percutaneous left atrial appendage closure.

94 th 17.9% being detected >6 months after left atrial appendage closure.

95 In the study, we performed left atrial appendage closure.

96 profound and of longer duration for the left atrial appendage compared with the left atrium as a whol

97 This study compared left atrial and left atrial appendage contraction velocities in sinus rhythm

98 In patients, left atrial appendage contraction velocities measured during

99 Peak left atrial appendage contraction velocities were significant

100 on at all time intervals as assessed by left atrial appendage contraction velocity (LAACV) was signif

101 ld (DFT) testing was performed using a right atrial appendage/coronary sinus lead configuration in 38

102 nscatheter aortic valve replacement and left atrial appendage device occlusion, is being increasingly

103 urgery, histopathologic changes in the right atrial appendage do not predict POAF.

104 ardiac myocytes were isolated from the right atrial appendage during CABG.

105 ading to stasis of blood flow following left atrial appendage electrical isolation (LAAEI) could lead

106 fibrillation are depressed relative to left atrial appendage emptying velocities measured during atr

107 4.9 cm, p < 0.0001 and lower mean peak left atrial appendage emptying velocity (LAAEV), 38 versus 56

108 spontaneous echo contrast, we measured left atrial appendage emptying velocity and calculated shear

109 ntricular diastolic function, and lower left atrial appendage emptying velocity were independently as

110 -determined transmitral diastolic flow, left atrial appendage emptying, and pulmonary venous flow), c

111 vein, ganglionated plexi ablation, and left atrial appendage excision with optional additional lines

112 port LAAO, the randomized LeAAPS trial (Left Atrial Appendage Exclusion for Prophylactic Stroke Reduc

113 llow-up continues to support a role for left atrial appendage exclusion from the central circulation

114 ricular tachycardia ablation and Lariat left atrial appendage exclusion.

115 atrial fibrillation, left atrial size, left atrial appendage flow velocities and thrombus.

116 s with atrial flutter exhibited greater left atrial appendage flow velocities before cardioversion th

117 After cardioversion, left atrial appendage flow velocities decreased compared with

118 Left atrial appendages from 239 patients stratified by corona

119 METHODS AND Human CPCs from the right atrial appendages from children of different ages underg

120 Human CPCs from the right atrial appendages from children of different ages underg

121 Right-atrial appendages from control sinus rhythm patients or

122 proteins (Kv1.5 and Kv2.1) in left and right atrial appendages from patients (n = 28) in normal sinus

123 In contrast, atrial appendages from patients in persistent atrial fib

124 rbored a cleavage site that was not found in atrial appendages from patients in sinus rhythm.

125 iques and immunoconfocal microscopy in right atrial appendages from patients with ischemic heart dise

126 ctivity and glutathione were also present in atrial appendages from surgical patients >=75 years as c

127 coproteins were identified in left and right atrial appendages from the same patients.

128 The impaired left atrial appendage function after cardioversion was less p

129 ents with atrial flutter and to compare left atrial appendage function in the pericardioversion perio

130 ibrillation because of better preserved left atrial appendage function.

131 Tissue samples from the atrial appendages had a greater concentration of norepin

132 CSCs were isolated from the right atrial appendage harvested and processed during surgery.

133 In this setting, thrombus in the left atrial appendage has been found to be the source of stro

134 typically results from thrombus in the left atrial appendage has led to the development of mechanica

135 he intramyocardial blood vessels of the left atrial appendage have an increased CML presence and proi

136 ficantly higher in blood vessels of the left atrial appendage in AF patients as compared to controls,

137 by Prophylactic Surgical Closure of the Left Atrial Appendage in Patients Undergoing Bioprosthetic Ao

138 in alcohol intake, and occlusion of the left atrial appendage in patients with atrial fibrillation an

139 has, for the first time, implicated the left atrial appendage in the pathogenesis of stroke in atrial

140 trial fibrillation, suggesting that the left atrial appendage is mechanically "stunned."

141 Incessant FAT originating in the atrial appendages is more likely to respond to ivabradin

142 ssigned to undergo empirical electrical left atrial appendage isolation along with extensive ablation

143 e effectiveness of empirical electrical left atrial appendage isolation for the treatment of LSPAF.

144 (Effect of Empirical Left Atrial Appendage Isolation on Long-term Procedure Outcom

145 repeat procedures, empirical electrical left atrial appendage isolation was performed in all patients

146 x coronary artery, and catheters in the left atrial appendage, jugular and carotid vessels.

147 , or by equivalent test pacing from the left atrial appendage (LAA) at 5% or 50% greater than the sin

148 ficant effect on blood viscosity in the left atrial appendage (LAA) at low shear rates.

149 ard for the exclusion of thrombi in the left atrial appendage (LAA) before ablation for atrial fibril

150 This study investigated the left atrial appendage (LAA) by computed tomography (CT) and m

151 as to assess the safety and efficacy of left atrial appendage (LAA) closure in nonvalvular atrial fib

152 o determine which surgical technique of left atrial appendage (LAA) closure is most successful by ass

153 to determine the efficacy and safety of left atrial appendage (LAA) closure via a percutaneous LAA li

154 Randomized trials of left atrial appendage (LAA) closure with the Watchman device

155 Administration (FDA) clinical trials of left atrial appendage (LAA) closure, a postimplantation perid

156 e empirical electrical isolation of the left atrial appendage (LAA) could improve success at follow-u

157 incidence of incomplete ligation of the left atrial appendage (LAA) during mitral valve surgery.

158 Left atrial appendage (LAA) electric isolation is reported to

159 term effect of a brief episode of AF on left atrial appendage (LAA) emptying velocity is unknown.

160 his study was to evaluate the impact of left atrial appendage (LAA) exclusion on short-term outcomes

161 haracterization of left atrial (LA) and left atrial appendage (LAA) flow dynamics in patients with at

162 d in sinus rhythm at 6 months to assess left atrial appendage (LAA) function were included in this an

163 The left atrial appendage (LAA) has been identified as a predomin

164 f stroke and systemic embolism, and the left atrial appendage (LAA) has been identified as a principa

165 The left atrial appendage (LAA) is an underestimated site of init

166 Prophylactic exclusion of the left atrial appendage (LAA) is often performed during cardiac

167 The left atrial appendage (LAA) is the source of the vast majorit

168 Electric left atrial appendage (LAA) isolation (LAAI) may occur during

169 Transcatheter left atrial appendage (LAA) ligation may represent an alterna

170 Left atrial appendage (LAA) ligation with the Lariat device i

171 Percutaneous left atrial appendage (LAA) occlusion and novel pharmacologic

172 Left atrial appendage (LAA) occlusion provides an alternative

173 endage Occlusion Study III) showed that left atrial appendage (LAA) occlusion reduces the risk of isc

174 nonvalvular atrial fibrillation (NVAF), left atrial appendage (LAA) occlusion was noninferior to warf

175 ansluminal coronary angioplasty (PTCA), left atrial appendage (LAA) occlusion, patent foramen ovale (

176 Left atrial appendage (LAA) procedures have been developed to

177 uency and clinical impact of incomplete left atrial appendage (LAA) sealing and consequent peri-devic

178 a CHADS(2) score with left atrial (LA)/left atrial appendage (LAA) spontaneous echo contrast, sludge

179 stroke is thought to be associated with left atrial appendage (LAA) thrombi.

180 e due almost exclusively to emboli from left atrial appendage (LAA) thrombi.

181 l fibrillation (AF) develops persistent left atrial appendage (LAA) thrombus despite optimal oral ant

182 The left atrial appendage (LAA) was snap-frozen in situ after pac

183 modality of choice for visualizing the left atrial appendage (LAA).

184 y, the filling and emptying jets of the left atrial appendage (LAA).

185 can produce 4-dimensional images of the left atrial appendage (LAA).

186 afety and effectiveness of percutaneous left atrial appendage ligation adjunctive to planned pulmonar

187 re randomized in a 2:1 ratio to undergo left atrial appendage ligation and pulmonary vein isolation o

188 ricular tachycardia ablation and Lariat left atrial appendage ligation that involve the epicardial sp

189 crometers; n=120) dissected from human right atrial appendages (n=78) were cannulated at a distending

190 We evaluated left atrial appendage obliteration in high-risk patients with

191 myofibers prepared from samples of the right atrial appendage obtained from nondiabetic (n = 13) and

192 HCRAs were dissected from right atrial appendages obtained from patients during cardiac

193 pare miR-21 levels in isolated myocytes from atrial appendages obtained from patients in sinus rhythm

194 (AMPLATZER Amulet Left Atrial Appendage Occluder [LAAO] Investigational Device

195 ffsetting potential benefits and making left atrial appendage occlusion (LAAO) a potentially promisin

196 he 90 patients with stroke, 84 received left atrial appendage occlusion (LAAO) devices.

197 ty of DCCV in patients with endocardial left atrial appendage occlusion (LAAO) devices.

198 Left atrial appendage occlusion (LAAO) to prevent stroke in p

199 Background At follow-up CT after left atrial appendage occlusion (LAAO), hypoattenuation thick

200 wed 301 consecutive patients undergoing left atrial appendage occlusion at Aarhus University Hospital

201 ere novel oral anticoagulants, Watchman left atrial appendage occlusion device (DEVICE), and warfarin

202 re Technology, patients with a WATCHMAN left atrial appendage occlusion device had consistently low r

203 to exclude left atrial thrombus and in left atrial appendage occlusion device implantation.

204 t failure, anticoagulation therapy, and left atrial appendage occlusion devices.

205 ciaries >=65 years of age who underwent left atrial appendage occlusion from April 1, 2016, to August

206 roke, site-specific therapy directed at left atrial appendage occlusion has been now studied for stro

207 trials are addressing the usefulness of left atrial appendage occlusion in both primary and secondary

208 Left atrial appendage occlusion indication was based on the E

209 vice-related thrombosis (DRT) following left atrial appendage occlusion is a rare but feared complica

210 In-hospital PE during transcatheter left atrial appendage occlusion is infrequent but associated

211 atrioventricular junction ablation, and left atrial appendage occlusion may be useful in appropriatel

212 mic embolism was lower with concomitant left atrial appendage occlusion performed during the surgery

213 eded to test the safety and efficacy of left atrial appendage occlusion plus anticoagulation versus c

214 pital and physician volume and WATCHMAN left atrial appendage occlusion procedural success overall an

215 Among 97 185 patients in the Left Atrial Appendage Occlusion registry undergoing WATCHMAN

216 e National Cardiovascular Data Registry Left Atrial Appendage Occlusion Registry, the most common pro

217 LAAOS III (Left Atrial Appendage Occlusion Study III) showed that left a

218 Among patients undergoing left atrial appendage occlusion with the first-generation Wat

219 Left atrial appendage occlusion with WATCHMAN has emerged as

220 bolic risk assessment, anticoagulation, left atrial appendage occlusion, atrial fibrillation catheter

221 ical, percutaneous therapies, including left atrial appendage occlusion, for stroke prevention have e

222 stroke prevention strategies, including left atrial appendage occlusion, in patients with atrial fibr

223 Keywords: Device-related Thrombosis, Left Atrial Appendage Occlusion, Meta-analysis, Transesophage

224 ents underwent remapping at the time of left atrial appendage occlusion, which showed CS and LAA isol

225 after cardioversion, and techniques of left atrial appendage occlusion.

226 s from rat left ventricle and from the right atrial appendage of patients undergoing elective cardiac

227 osis on conduction velocity (CV) in the left atrial appendage of patients with AF.

228 e performed on DNA from lymphocytes and left atrial appendages of 34 patients (25 with AF).

229 uced by > 50% in both the left and the right atrial appendages of AF patients.

230 ed to study conduction in the right and left atrial appendages of isolated Langendorff-perfused murin

231 The atrial appendages of patients undergoing coronary artery

232 asured in arterioles isolated from the right atrial appendages of patients with HFpEF.

233 Myostatin expression was decreased in atrial appendages of patients with persistent atrial fib

234 cretory phenotype of cardiomyocytes from the atrial appendages of the heart led to the discovery that

235 n using differential coronary sinus and left atrial appendage pacing techniques encounters a pitfall,

236 k using differential coronary sinus and left atrial appendage pacing techniques in patients with left

237 ssociated with lower odds of persisting left atrial appendage patency (odds ratio, 0.46; 95% CI: 0.27

238 Computed tomography-based left atrial appendage patency and PDL were present in 54.9% a

239 eous echo contrast (RR 3.7, p < 0.001), left atrial appendage peak flow velocities < or = 20 cm/s (RR

240 The percutaneous approach via the right atrial appendage provides a rapid, safe route to access

241 Electrodes were positioned in the right atrial appendage (RA), left subclavian vein (LSV), proxi

242 s of a shock between electrodes in the right atrial appendage (RAA) and coronary sinus (CS).

243 ir enzymatic sources in samples of the right atrial appendage (RAA) from 303 patients undergoing card

244 and isolated atrial myocytes from the right atrial appendage (RAA) of patients undergoing cardiac su

245 gy of the standard lead configuration, right atrial appendage (RAA) to coronary sinus (CS), was reduc

246 tion electrodes were positioned in the right atrial appendage (RAap), distal coronary sinus (DCS), pr

247 Right atrial appendage samples were prospectively collected du

248 NAs were highly correlated in 233 human left atrial appendage samples.

249 Left atrial appendage shear rates were also higher in patient

250 Left atrial appendage stunning also occurs in patients with a

251 Left atrial appendage stunning has recently been proposed as

252 This study sought to determine whether left atrial appendage stunning occurs in patients with atrial

253 The PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patien

254 multicenter PROTECT AF study (Watchman Left Atrial Appendage System for Embolic Protection in Patien

255 The Watchman Left Atrial Appendage System for Embolic Protection in Patien

256 d clinical trials, PROTECT-AF (Watchman Left Atrial Appendage System for Embolic PROTECTion in Patien

257 The PROTECT AF (WATCHMAN Left Atrial Appendage System for Embolic Protection in Patien

258 follow-up from the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patien

259 predominantly from PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patien

260 olic function and regional left atrial (left atrial appendage) systolic function upon resumption of s

261 In human right atrial appendages, TERT was localized in mitochondria an

262 , as well as the pericardium, right and left atrial appendages, the junction of the right atrium and

263 onferring moderate risk) more frequently had atrial appendage thrombi (RR 2.6, p < 0.001) and reduced

264 Warfarin inhibits formation of atrial appendage thrombi and markedly reduces cardioembo

265 Left atrial appendage thrombosis and embolization is the prin

266 Patients without atrial cavity thrombus or atrial appendage thrombus by TEE are cardioverted on ach

267 ng thrombosis may contribute to formation of atrial appendage thrombus, but these conditions remain i

268 serted after induction of GA to exclude left atrial appendage thrombus, define cardiac function, and

269 ture AT termination, noninducibility or left atrial appendage thrombus.

270 utine cardiac surgical procedures from right atrial appendage tissue discarded from 2 age groups: neo

271 Left atrial appendage tissue from 33 AF patients and 9 contro

272 Right atrial appendage tissue was collected from 34 patients,

273 Human atrial appendage tissues from matched cohorts in sinus r

274 To address this subject, human left atrial appendage tissues were obtained from 10 patients

275 Three of these were right atrial appendage-to-right ventricle APs, and epicardial

276 to evaluate the effects of percutaneous left atrial appendage transcatheter occlusion (PLAATO) on the

277 HA functional class, ejection fraction, left atrial appendage velocity, and medications in patients w

278 Cx40 in one allele (Cx40+/-) included bifid atrial appendage, ventricular septal defect, tetralogy o

279 PROTECT AF (Percutaneous Closure of the Left Atrial Appendage Versus Warfarin Therapy for Prevention

280 PROTECT AF (Percutaneous Closure of the Left Atrial Appendage Versus Warfarin Therapy for Prevention

281 PROTECT AF (Percutaneous Closure of the Left Atrial Appendage Versus Warfarin Therapy for Prevention

282 ollow-up of Percutaneous Closure of the Left Atrial Appendage Versus Warfarin Therapy for Prevention

283 annulus along the posterior base of the left atrial appendage visualized by selective angiography.

284 Right atrial appendage was collected from 8 male patients pre

285 FAT originating in the atrial appendages was a predictor of ivabradine response

286 ricuspid valve, interatrial septum, and left atrial appendage were obtained, followed by a left ventr

287 is, the distal coronary sinus, and the right atrial appendage were outside the circuit.

288 Arterioles dissected from right atrial appendage were studied with video microscopy, mem

289 Excised right atrial appendages were analyzed histologically to charac

290 ulmonary bypass, paired samples of the right atrial appendages were obtained before venous cannulatio

291 Thirty-five left atrial appendages were obtained during AF surgery.

292 Methods and Results-- Right atrial appendages were obtained from AF patients undergo

293 In the LAAI group, 77 of 82 left atrial appendages were successfully isolated with subseq

294 Human atrial appendages were used to assess the protein levels

295 erved at the left atrial sites and the right atrial appendage, whereas disorganized atrial electrogra

296 l parameters of the left atrium and the left atrial appendage which have been shown to be associated

297 CVL was higher in left atrial appendages with thick compared with thin intersti

298 tropy in the posterior left atrium than left atrial appendage, with the decrease in Shannon entropy c

299 ved an adequate seal of the neck of the left atrial appendage without significant effect on the struc

300 othesized that partial clipping of the right atrial appendage would increase the blood flow to the le